Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

AI tool may support dermatologists in assessing skin lesions for cancer risk (opens in a new tab)

medicalxpress.com · 2026-10-23

Short answerEvidenceSource

Short answer

Not assessed

Check incomplete.

We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Source study identified.

A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.

View article claims
3
Then inspect each claim

Evidence layer

Claim by claim

A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.

Claim 1 of 6Not checkedMayo Clinic researchers have found that an artificial intelligence tool may provide dermatologists with additional information to help assess whether skin lesions are cancerous and inform decisions about whether to biopsy or monitor them.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 2 of 6Not checkedThe tool, called Dermoscopy Explainable Intelligence (DEXI), assigns lesions a score from 0.0 to 10.0 based on image characteristics associated with cancer risk and identifies features such as asymmetry, border and color that contribute to the score.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 3 of 6Not checkedUsing a threshold of 3.0, DEXI correctly identified 93.4% of cancerous lesions and 75% of noncancerous lesions.View evidenceHide evidence

As stated93.4% and 75%

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 4 of 6Not checkedThe retrospective study included 178 patients and analyzed 261 lesions with a DEXI score and a tissue-confirmed diagnosis.View evidenceHide evidence

As stated178 patients; 261 lesions

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 5 of 6Not checkedResearchers reported that cancerous lesions had significantly higher DEXI scores than noncancerous lesions, with average scores of 7.8 for nonmelanoma skin cancers, 6.0 for melanomas, and 2.5 for noncancerous lesions.View evidenceHide evidence

As stated7.8, 6.0, and 2.5

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 6 of 6Not checkedThe researchers said DEXI was less effective for severely atypical nevi and early evolving melanomas, and should not be used in isolation because it does not account for patient-specific factors such as age, medications and melanoma history.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Dermoscopy Explainable Intelligence Performance in Evaluating Melanoma and Non-Melanoma Skin Cancer

Mayo Clinic Proceedings · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, Europe PMC, PubMed · 33 candidate papers

Selected

Dermoscopy Explainable Intelligence Performance in Evaluating Melanoma and Non-Melanoma Skin Cancer

Mayo Clinic Proceedings · 2026 · Crossref

Source (opens in a new tab)

And 27 more candidates considered.